Business Context and Reporting Period
This Form 6-K filing by Innate Pharma S.A. is dated September 17, 2026. The report serves primarily to incorporate by reference a press release (Exhibit 99.1) into the company's existing registration statements on Form F-3 and Form S-8. The filing does not contain the full text of the press release or specific operational details within the body of the document.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. As this document is a cover sheet for an incorporated exhibit, specific financial data points are not disclosed in the provided text.
Material Changes
No material changes regarding financial performance or operations are described in the filing text. The document focuses on regulatory compliance and the incorporation of external materials rather than reporting period-over-period changes.
Guidance, Outlook, and Risks
The filing text does not provide specific guidance, outlook, management commentary, risks, or contingencies. It notes the existence of a press release containing a quotation from CEO Jonathan Dickinson but explicitly excludes the text of that quotation and related webcast links from the incorporation by reference.
Investor Verification Checklist
- Verify the content of Exhibit 99.1 (Press Release dated September 17, 2026) for actual operational or financial updates.
- Confirm the status of the registration statements on Form F-3 (File No. 333-276164) and Form S-8 (File No. 333-282031) to understand the context of the incorporation.
- Review the excluded quotation from CEO Jonathan Dickinson in the original press release for management sentiment.